Lead Sponsor

Gilead Sciences

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

•Male or females from 40 to 80 years of age
•Diagnosis of IPF
•Honeycombing (fibrosis in the lung) on high-resolution computerised tomography (HRCT) scan of less than or equal to 5%
•Willing and able to have 2 right heart catheterizations performed
•Willing to have monthly lab tests to monitor liver function
•Able to perform the 6 minute walk test (indicated adequate physical function)
•Must have meet lung function requirements
•Normal liver function tests
•Negative serum pregnancy test
•Willing to use at least 2 reliable methods of contraception
•Able to understand and willing to sign informed consent form

•No restrictive lung disease (other than usual interstitial pneumonia or IPF)
•No obstructive lung disease
•No recent or active respiratory exacerbations
•No recent hospitalization for an IPF exacerbation
•No recent history of alcohol abuse
•Chronic sildenafil (or same drug class) use for pulmonary hypertension
•Chronic treatment with certain medications for IPF within 30 days of randomization
•No other serious medical conditions

Related studies

NCT06238622 · Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

NCT07299695 · Idiopathic Pulmonary Fibrosis, Acute Exacerbation of Idiopathic Pulmonary Fibrosis

NCT07466420 · Fibrotic Interstitial Lungs Diseases, Idiopathic Pulmonary Fibrosis (IPF), and more

NCT06241560 · Idiopathic Pulmonary Fibrosis

NCT05674994 · Acute Exacerbation of Idiopathic Pulmonary Fibrosis

(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF